Smith Jason Drew (CIK 1821479) reported 12 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-09-09). Recent activity: Buy URGN (3,334 shares), Sell URGN (1,519 shares), Buy URGN (5,500 shares), Sell URGN (2,654 shares), Buy URGN (3,333 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | UroGen Pharma Ltd. (URGN) | General Counsel | Buy | 3,334 | $0 |
| 2026-09-09 | UroGen Pharma Ltd. (URGN) | General Counsel | Sell | 1,519 | $64,618 |
| 2026-02-11 | UroGen Pharma Ltd. (URGN) | General Counsel | Buy | 5,500 | $0 |
| 2026-02-11 | UroGen Pharma Ltd. (URGN) | General Counsel | Sell | 2,654 | $52,257 |
| 2026-02-11 | UroGen Pharma Ltd. (URGN) | General Counsel | Buy | 3,333 | $0 |
| 2026-02-11 | UroGen Pharma Ltd. (URGN) | General Counsel | Sell | 1,608 | $31,662 |
| 2026-02-11 | UroGen Pharma Ltd. (URGN) | General Counsel | Buy | 6,667 | $0 |
| 2026-02-11 | UroGen Pharma Ltd. (URGN) | General Counsel | Sell | 3,217 | $63,343 |
| 2025-09-09 | UroGen Pharma Ltd. (URGN) | General Counsel | Buy | 3,333 | $0 |
| 2025-09-09 | UroGen Pharma Ltd. (URGN) | General Counsel | Sell | 1,520 | $29,047 |
| 2025-07-30 | UroGen Pharma Ltd. (URGN) | General Counsel | Buy | 16,500 | $0 |
| 2025-07-30 | UroGen Pharma Ltd. (URGN) | General Counsel | Sell | 7,522 | $143,971 |
来源：SEC Form 4 申报文件 · 截至 2026-09-09